麻豆原创

Published on 麻豆原创 Research Reports庐 Inc. ()

麻豆原创 > Global Controlled Substances 麻豆原创 Research Report 2023

Global Controlled Substances 麻豆原创 Research Report 2023

Publication ID: 
PB504238794
Publication Date: 
April 25, 2023
Pages: 
88
Publisher: 
MRRPB5
Countries: 
Global [1]
USD 2,900.00

Please choose the suitable license type from above. More details are given under tab "Report License Types" below.

Pharmaceutical Manufacturing [2]
Healthcare [3]
Pharma & Healthcare [4]
Description: 

Highlights

The global Controlled Substances market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

North America has traditionally been the most lucrative market for controlled substances, with sales estimated to record a Y-o-Y of 5.0% in 2019 over 2018. This can be attributes in part to legalization of various forms of marijuana in the US, along with the recent approval of recreational marijuana sales in Canada.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Controlled Substances, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Controlled Substances.

The Controlled Substances market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Controlled Substances market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Controlled Substances companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.

By Company

Johnson & Johnson

Pfizer

Siegfried AG

GlaxoSmithKline

Teva Pharmaceuticals

Mylan

Takeda Pharmaceutical

Sun Pharmaceutical

Daiichi Sankyo

Akorn Inc

Tilray

Medical Marijuana, Inc

Consort Medical

Purdue Pharma

Segment by Type

Opioids

Stimulants

Depressants

Marijuana

Others

Segment by Application

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

By Region

North America

United States

Canada

Europe

Germany

France

UK

Italy

Russia

Nordic Countries

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Controlled Substances companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents: 

1 Report Overview

1.1 Study Scope

1.2 麻豆原创 Analysis by Type

1.2.1 Global Controlled Substances 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029

1.2.2 Opioids

1.2.3 Stimulants

1.2.4 Depressants

1.2.5 Marijuana

1.2.6 Others

1.3 麻豆原创 by Application

1.3.1 Global Controlled Substances 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029

1.3.2 Hospital Pharmacies

1.3.3 Retail Pharmacies

1.3.4 Online Pharmacies

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2 Global Growth Trends

2.1 Global Controlled Substances 麻豆原创 Perspective (2018-2029)

2.2 Controlled Substances Growth Trends by Region

2.2.1 Global Controlled Substances 麻豆原创 Size by Region: 2018 VS 2022 VS 2029

2.2.2 Controlled Substances Historic 麻豆原创 Size by Region (2018-2023)

2.2.3 Controlled Substances Forecasted 麻豆原创 Size by Region (2024-2029)

2.3 Controlled Substances 麻豆原创 Dynamics

2.3.1 Controlled Substances Industry Trends

2.3.2 Controlled Substances 麻豆原创 Drivers

2.3.3 Controlled Substances 麻豆原创 Challenges

2.3.4 Controlled Substances 麻豆原创 Restraints

3 Competition Landscape by Key Players

3.1 Global Top Controlled Substances Players by Revenue

3.1.1 Global Top Controlled Substances Players by Revenue (2018-2023)

3.1.2 Global Controlled Substances Revenue 麻豆原创 Share by Players (2018-2023)

3.2 Global Controlled Substances 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Controlled Substances Revenue

3.4 Global Controlled Substances 麻豆原创 Concentration Ratio

3.4.1 Global Controlled Substances 麻豆原创 Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Controlled Substances Revenue in 2022

3.5 Controlled Substances Key Players Head office and Area Served

3.6 Key Players Controlled Substances Product Solution and Service

3.7 Date of Enter into Controlled Substances 麻豆原创

3.8 Mergers & Acquisitions, Expansion Plans

4 Controlled Substances Breakdown Data by Type

4.1 Global Controlled Substances Historic 麻豆原创 Size by Type (2018-2023)

4.2 Global Controlled Substances Forecasted 麻豆原创 Size by Type (2024-2029)

5 Controlled Substances Breakdown Data by Application

5.1 Global Controlled Substances Historic 麻豆原创 Size by Application (2018-2023)

5.2 Global Controlled Substances Forecasted 麻豆原创 Size by Application (2024-2029)

6 North America

6.1 North America Controlled Substances 麻豆原创 Size (2018-2029)

6.2 North America Controlled Substances 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029

6.3 North America Controlled Substances 麻豆原创 Size by Country (2018-2023)

6.4 North America Controlled Substances 麻豆原创 Size by Country (2024-2029)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Controlled Substances 麻豆原创 Size (2018-2029)

7.2 Europe Controlled Substances 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029

7.3 Europe Controlled Substances 麻豆原创 Size by Country (2018-2023)

7.4 Europe Controlled Substances 麻豆原创 Size by Country (2024-2029)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Controlled Substances 麻豆原创 Size (2018-2029)

8.2 Asia-Pacific Controlled Substances 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029

8.3 Asia-Pacific Controlled Substances 麻豆原创 Size by Region (2018-2023)

8.4 Asia-Pacific Controlled Substances 麻豆原创 Size by Region (2024-2029)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Controlled Substances 麻豆原创 Size (2018-2029)

9.2 Latin America Controlled Substances 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029

9.3 Latin America Controlled Substances 麻豆原创 Size by Country (2018-2023)

9.4 Latin America Controlled Substances 麻豆原创 Size by Country (2024-2029)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Controlled Substances 麻豆原创 Size (2018-2029)

10.2 Middle East & Africa Controlled Substances 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029

10.3 Middle East & Africa Controlled Substances 麻豆原创 Size by Country (2018-2023)

10.4 Middle East & Africa Controlled Substances 麻豆原创 Size by Country (2024-2029)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Johnson & Johnson

11.1.1 Johnson & Johnson Company Detail

11.1.2 Johnson & Johnson Business Overview

11.1.3 Johnson & Johnson Controlled Substances Introduction

11.1.4 Johnson & Johnson Revenue in Controlled Substances Business (2018-2023)

11.1.5 Johnson & Johnson Recent Development

11.2 Pfizer

11.2.1 Pfizer Company Detail

11.2.2 Pfizer Business Overview

11.2.3 Pfizer Controlled Substances Introduction

11.2.4 Pfizer Revenue in Controlled Substances Business (2018-2023)

11.2.5 Pfizer Recent Development

11.3 Siegfried AG

11.3.1 Siegfried AG Company Detail

11.3.2 Siegfried AG Business Overview

11.3.3 Siegfried AG Controlled Substances Introduction

11.3.4 Siegfried AG Revenue in Controlled Substances Business (2018-2023)

11.3.5 Siegfried AG Recent Development

11.4 GlaxoSmithKline

11.4.1 GlaxoSmithKline Company Detail

11.4.2 GlaxoSmithKline Business Overview

11.4.3 GlaxoSmithKline Controlled Substances Introduction

11.4.4 GlaxoSmithKline Revenue in Controlled Substances Business (2018-2023)

11.4.5 GlaxoSmithKline Recent Development

11.5 Teva Pharmaceuticals

11.5.1 Teva Pharmaceuticals Company Detail

11.5.2 Teva Pharmaceuticals Business Overview

11.5.3 Teva Pharmaceuticals Controlled Substances Introduction

11.5.4 Teva Pharmaceuticals Revenue in Controlled Substances Business (2018-2023)

11.5.5 Teva Pharmaceuticals Recent Development

11.6 Mylan

11.6.1 Mylan Company Detail

11.6.2 Mylan Business Overview

11.6.3 Mylan Controlled Substances Introduction

11.6.4 Mylan Revenue in Controlled Substances Business (2018-2023)

11.6.5 Mylan Recent Development

11.7 Takeda Pharmaceutical

11.7.1 Takeda Pharmaceutical Company Detail

11.7.2 Takeda Pharmaceutical Business Overview

11.7.3 Takeda Pharmaceutical Controlled Substances Introduction

11.7.4 Takeda Pharmaceutical Revenue in Controlled Substances Business (2018-2023)

11.7.5 Takeda Pharmaceutical Recent Development

11.8 Sun Pharmaceutical

11.8.1 Sun Pharmaceutical Company Detail

11.8.2 Sun Pharmaceutical Business Overview

11.8.3 Sun Pharmaceutical Controlled Substances Introduction

11.8.4 Sun Pharmaceutical Revenue in Controlled Substances Business (2018-2023)

11.8.5 Sun Pharmaceutical Recent Development

11.9 Daiichi Sankyo

11.9.1 Daiichi Sankyo Company Detail

11.9.2 Daiichi Sankyo Business Overview

11.9.3 Daiichi Sankyo Controlled Substances Introduction

11.9.4 Daiichi Sankyo Revenue in Controlled Substances Business (2018-2023)

11.9.5 Daiichi Sankyo Recent Development

11.10 Akorn Inc

11.10.1 Akorn Inc Company Detail

11.10.2 Akorn Inc Business Overview

11.10.3 Akorn Inc Controlled Substances Introduction

11.10.4 Akorn Inc Revenue in Controlled Substances Business (2018-2023)

11.10.5 Akorn Inc Recent Development

11.11 Tilray

11.11.1 Tilray Company Detail

11.11.2 Tilray Business Overview

11.11.3 Tilray Controlled Substances Introduction

11.11.4 Tilray Revenue in Controlled Substances Business (2018-2023)

11.11.5 Tilray Recent Development

11.12 Medical Marijuana, Inc

11.12.1 Medical Marijuana, Inc Company Detail

11.12.2 Medical Marijuana, Inc Business Overview

11.12.3 Medical Marijuana, Inc Controlled Substances Introduction

11.12.4 Medical Marijuana, Inc Revenue in Controlled Substances Business (2018-2023)

11.12.5 Medical Marijuana, Inc Recent Development

11.13 Consort Medical

11.13.1 Consort Medical Company Detail

11.13.2 Consort Medical Business Overview

11.13.3 Consort Medical Controlled Substances Introduction

11.13.4 Consort Medical Revenue in Controlled Substances Business (2018-2023)

11.13.5 Consort Medical Recent Development

11.14 Purdue Pharma

11.14.1 Purdue Pharma Company Detail

11.14.2 Purdue Pharma Business Overview

11.14.3 Purdue Pharma Controlled Substances Introduction

11.14.4 Purdue Pharma Revenue in Controlled Substances Business (2018-2023)

11.14.5 Purdue Pharma Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

Companies Mentioned: 

Johnson & Johnson

Pfizer

Siegfried AG

GlaxoSmithKline

Teva Pharmaceuticals

Mylan

Takeda Pharmaceutical

Sun Pharmaceutical

Daiichi Sankyo

Akorn Inc

Tilray

Medical Marijuana, Inc

Consort Medical

Purdue Pharma

License Types: 

Single User License (PDF)

  • This license allows for use of a publication by one person.
  • This person may print out a single copy of the publication.
  • This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
  • This person cannot share the publication (or any information contained therein) with any other person or persons.
  • Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
  • Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

  • This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
  • These users may print out a single copy of the publication.
  • These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
  • These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
  • Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
  • Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

  • This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
  • Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
  • These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

Source URL:/mrrpb5/global-controlled-substances-market-research-report-2023

Links
[1] /countries/global[2] /pharmaceutical-manufacturing[3] /healthcare[4] /pharma-healthcare